01 — At a Glance
The Most Confusing “Growth” Story in Indian Chemicals
- 52-Week High / Low₹596 / ₹336
- Q3 FY26 Revenue₹411 Cr
- Q3 FY26 PAT₹33.8 Cr
- Q3 FY26 EPS₹5.02
- Annualised EPS (Q3×4)₹20.08
- Book Value (Mar 2025)₹149
- Price to Book3.43x
- 9M FY26 Revenue₹1,159 Cr
- 9M FY26 PAT₹98.8 Cr
- Debt / Equity (Mar 2025)0.42x
The Auditor’s Rant: Vishnu Chemicals posted ₹411 crore revenue in Q3 FY26, up 2.5% QoQ and 10.8% YoY (9M basis). PAT hit ₹33.8 crore, but margins are stuck in mid-teens. Not because they’re incompetent—because they’re aggressively integrating backward (chrome ore mine), forward (strontium, DMSO), and sideways (barium chemicals, green chrome oxide). Meanwhile, the stock trades at 24.9x P/E and the dividend yield is 0.06%. That’s not a dividend. That’s a rounding error masquerading as shareholder returns. The playbook is clear: reinvest everything or become irrelevant.
02 — Introduction
The Chemical Company Pretending It’s a Mining Conglomerate
Vishnu Chemicals is the weird uncle at the family reunion who kept his job at the factory, got really good at it, then decided to buy the mine that supplies the factory, the rubber plantation that supplies the plastics plant, and a controlling stake in the guy who sells the finished goods. All while everyone else is still making the same thing they made in 1995.
Founded in 1989, Vishnu makes chromium chemicals and barium compounds for 57 countries. Big deal—there are 195 countries in the world. But in the 12 industries they serve (auto, pharma, leather, paints, tiles, etc.), they’re the dominant player. They command 51% market share in chromium chemicals in India. That’s basically India’s entire chromium supply in one ₹3,430 crore market cap. Hilarious asymmetry: a ₹3,430 crore company is literally The Company for a critical input used by billion-rupee corporations.
Q3 FY26 was a study in “we’re optimizing for scale, not immediate profitability.” Revenue grew 10.8% (9M basis), PAT grew 12.7% (9M), but margins stayed stuck at 15% EBITDA because they’re dumping capital into three acquisitions: Ramadas Minerals (barytes), Jayansree Pharma (now Vishnu Strontium), and—most audaciously—a chrome ore mine in South Africa. Management’s concall was refreshingly honest: “EBITDA margins will continue to get to the 20% level by FY28.” Translation: “we’re sacrificing now, you’ll thank us later.”
Concall Insight (Feb 2026): When asked about margin expansion, management didn’t dodge: “the company is explicitly managing toward a mix-led margin expansion pathway with a stated goal of ~20% EBITDA margin by FY28.” No Excel spreadsheet gymnastics. Just raw business strategy. Respect.
03 — Business Model: Vertical Integration Edition
They Make Chemicals. Then They Made Mines. Then They Made Everything.
Vishnu’s core business is simple: buy cheap raw materials, convert them to specialty chemicals, sell globally for 10–20x markup. Repeat for 35 years. The challenge? 44–50% of their cost of goods sold is raw materials—chrome ore, barytes, soda ash—and you don’t control the price unless you own the mine. Enter Act 2: acquisition spree.
Timeline of Obsession: FY24 acquired Ramadas Minerals for barytes beneficiation (backward integration, supply security). FY25 acquired Jayansree Pharma (now Vishnu Strontium) to manufacture strontium carbonate—a new forward-integration product used in EV batteries, glass, ceramics, and paints. Then in November 2025, they completed acquisition of a South African chrome ore mining complex with ~10 million tonnes of reserves for ₹58 crore.
Current revenue split: Domestic 54%, Exports 46%. Mix is deliberately balanced because one region going soft hurts volume less. Product portfolio now spans chromium chemicals (sodium dichromate, basic chromium sulphate, chrome oxide green), barium compounds (barium carbonate, precipitated barium sulphate), and new entrants (strontium carbonate for EV batteries, upcoming DMSO and chrome metal).
Capacity utilization varies wildly: sodium dichromate at 85%, barium carbonate at 67%, and strontium at 20–25% (because customer approvals are still pending, expected end-Q4 FY26). Management’s honest: they’re operating at 20–25% on purpose. When you just launched a new product, ramping to 80%+ is the goal, not the achievement.
Chromium Capacity80,000MTPA
Barium Capacity90,000MTPA
Strontium Capacity10,000MTPA (expandable)
Chrome Ore Mine10M TonnesReserves (South Africa)
The Vertical Integration Philosophy: Management said it explicitly: “secured ~10 million tonnes of chrome ore reserves (with 4 lakh tonnes immediately accessible for 2.5–3 years’ needs), which will stabilize raw material costs, which constitutes 44–50% of expenses.” They’re not building a mining company—they’re eliminating a cost centre. When your COGS is half the revenue, controlling the top line of that COGS is not luxury. It’s survival.
💬 Question for you: If a chemicals company owns a mine, is it still a chemicals company? Or has it levelled up to industrial conglomerate? What’s the difference between vertical integration and distraction? Comment below.
04 — Financials Overview
Q3 FY26: The Numbers (Quarterly Results)
Result type: Quarterly Results | Q3 FY26 EPS: ₹5.02 | Annualised EPS (Q3×4): ₹20.08 | 9M FY26 YoY PAT growth: +12.7%
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 411.3 | 370.8 | 401.1 | +10.9% | +2.5% |
| Gross Profit | 184 | 173 | 173 | +6.5% | +6.5% |
| EBITDA | 61.7 | 58 | 58 | +6.4% | +6% |
| EBITDA Margin % | 15.0% | 15.6% | 14.5% | -60 bps | +50 bps |
| PAT | 33.8 | 34.4 | 32.8 | -1.8% | +3.0% |
| EPS (₹) | 5.02 | 5.25 | 4.88 | -4.4% | +2.9% |
The Margin Story (Important): EBITDA margins compressing 60 bps YoY (15.6% → 15.0%) but expanding 50 bps QoQ (14.5% → 15.0%). Why? Global demand softness pushed selling prices down slightly, but working capital efficiency and gross margin expansion (43.1% Q2 → 44.8% Q3) offset the hit. Management was explicit on the concall: “we’re in a soft macroeconomic environment globally,” but India domestic demand remains “quite resilient.” The company is choosing to protect volume over margin—classic growth-phase sacrifice. By FY28, they want 20% EBITDA. Do the math: they need 500+ bps margin expansion from here. That requires the South Africa mine (raw material security) + product mix shift (strontium, DMSO, chrome oxide green, chrome metal) + scale.
05 — Valuation: Fair Value Range
Is ₹510 Cheap, Expensive, or Just Right? (Spoiler: It’s Complicated)
Method 1: P/E Based
Annualised Q3 FY26 EPS = ₹20.08. For a specialty chemicals company with 18% ROCE and vertical integration ambitions, a 22x–26x P/E is justified (industry median ~25.2x). At historical growth rates (5-year profit CAGR 41.6%), even 28x is defensible short-term.
Range: ₹442 – ₹557
Method 2: EV/EBITDA Based
TTM EBITDA (Mar 2025) = ₹240 Cr. Current EV = ₹3,669 Cr (enterprise value = market cap + net debt). EV/EBITDA = 15.3x. Quality specialty chemicals companies trade at 12x–16x. Vishnu’s integration strategy justifies upper band.
EBITDA range (post-integration FY27) estimated ~₹290 Cr. At 13x–15x:
Range: ₹475 – ₹575
Method 3: DCF Based (Margin Expansion Pathway)
Current operating CF: ~₹90 Cr annualised. FY27 FCF assumptions: 8% revenue growth + 17% EBITDA margin (vs. current 15%) + working capital optimization = ~₹110 Cr FCF. Terminal growth: 5%. WACC: 10%.
→ PV of 5-year FCFs (conservative): ~₹480 Cr
→ Terminal Value (5% growth / 5% cap rate): ~₹2,200 Cr
→ Total EV: ~₹2,680 Cr (less net debt ₹180 Cr) = ~₹2,500 Cr attributable to equity
Range: ₹420 – ₹540
Fair Min: ₹420
CMP: ₹510
Fair Max: ₹575
CMP ₹510
⚠️ EduInvesting Fair Value Range: ₹420 – ₹575. CMP ₹510 sits comfortably in the middle-to-upper half of the range. Valuation assumes successful execution of the margin expansion playbook (20% EBITDA by FY28) and timely completion of capex projects. This fair value range is for educational purposes only and is not investment advice.
06 — What’s Cooking: News, Triggers & Integration Drama
They’re Building an Empire. Slowly. Expensively.
